Circulating NAMPT/ PBEF /Visfatin and its cardiometabolic risk in young obese adults

Anitha G.1, Sivakumar J.2, Rasheed Khan M.3

1Department of Biochemistry, Sri Venkateshwara Medical College and Hospital and Research Centre, Puducherry, India
2Department of Biochemistry, Dhanalakshmi Srinivasan Medical College and Hospital, Perambalur, Tamil Nadu, India
3Department of Biochemistry, Srinivasan Medical College and Hospital, Trichy, Tamil Nadu, India

(Received: January 2022  Revised: May 2022  Accepted: June 2022)

Corresponding author: G. Anitha. Email: dranithagovind@gmail.com

ABSTRACT

Introduction and Aim: In this era of obesity pandemic, obesity related metabolic derangements has demanded more clinical attention due to its high rate of morbidity and mortality. Altered lipid profile and atherogenicity have increased the cardio metabolic risks, even in young adults and adolescents. Among various adipocytokines, visfatin/PBEF(pre-B-cell colony-enhancing factor)/NAMPT (nicotinamide phosphoribosyl transferase), predominantly secreted from the visceral fat, helps to predict the amount of fat that has a strong correlation with the derangement of cardio metabolic profile compared to the subcutaneous fat. The aim of this study is to determine the serum PBEF/visfatin levels in young obese, and to evaluate its correlation with body fat distribution, lipid parameters and the atherogenic index.

Materials and Methods: The subjects were 60 young obese adults in the age group of 18-35 years and age and sex matched 30 controls. Serum visfatin, lipid parameters and anthropometric indices- weight, height, HC (Hip circumference) and WC (waist circumference) were measured and BMI (Body mass index), WHR (waist–hip ratio) and atherogenic index (log of TG/ HDL-C) was calculated.

Results: NAMPT/PBEF/ Serum visfatin levels, BMI, WC, WHR, TG, LDL-C was significantly higher in young obese subjects than the controls (P< 0.05). The AI – atherogenic index of plasma was also significantly higher in young obese with P value < 0.01. There was positive correlation of TG, LDL-C and atherogenic index with serum NAMPT/visfatin levels. BMI also showed a significant positive correlation with r value of 0.56 (P= 0.01).

Conclusion: These results highlight that serum NAMPT/visfatin levels, due to its association with the atherogenic index, as a significant marker for assessing the cardio-metabolic risks in obese subjects. Higher atherogenic index of plasma in obese individuals focuses the impact of visceral fat in the initiation of atherosclerotic plaques even at a younger age group.

Keywords: NAMPT/PBEF/visfatin; atherogenic index; visceral fat; cardio metabolic risk.

INTRODUCTION

The prevalence of obesity is continuing to increase worldwide, affecting all age groups and has become the leading cause of death (1,2) due to its inevitable association with metabolic disorders like hypertension, diabetes, dyslipidemia, cardiovascular disorders, non-alcoholic fatty liver disease (NAFLD) and also certain cancerous conditions (3). A statistical report by WHO shows, 1 in 6 adults are obese worldwide and about 2.8 million die every year with overweight and metabolic disorders associated with obesity. In India, 213 million people are obese- 45.6% in urban and 22.5% in rural areas (4).

The factor that makes the adipose tissue a lethal organ is the adipocytokines it secretes, which alters the metabolic homeostasis increasing the incidence of cardiometabolic diseases in obese population (5,6). A relatively newer multifaceted adipocytokine, visfatin/NAMPT, is also found in bone marrow, skeletal muscle, liver and lymphocytes though principally secreted in visceral adipose tissue. Visfatin/NAMPT is also identified as a growth factor, pre B cell colony enhancing factor- 1 (PBEF1) in the lymphocytes that enhances the differentiation of stem cells to pre B cells (7,8). It is also identified as an intracellular enzyme, nicotinamide-5-phosphoribosyl -1-pyrophosphate transferase (NAMPT), which catalyses the rate limiting step in nicotinamide dinucleotide (NAD) synthesis (9). The interesting fact is that NAMPT is also found to be a potent proinflammatory mediator that participates in various inflammatory conditions. Obviously, inflammation of adipose tissue that induces insulin resistance and metabolic syndrome becomes the fundamental cause for the co-morbidities, related to obesity (10).

Dyslipidaemia, being the major metabolic derangement of obesity becomes the cause for the deposition of fat in the sub-endothelium of blood vessels that leads to atherosclerosis (11). Researchers have proved that Atherogenic Index of plasmaa s a significant predictor of atherosclerosis and...
dyslipidemia which can be calculated using the formula log TG/HDL (12).

There are two types of adipose tissue in humans, brown adipose tissue (BAT) and white adipose tissue (WAT). BAT is mainly involved in non-shivering thermogenesis, by which heat is produced by uncoupling of oxidative phosphorylation in mitochondria. WAT is the form of fat in which triglycerides is stored. White adipose tissue can be further divided as subcutaneous and abdominal depots, both of which have distinct physiological roles (13).

Visceral fat, the abdominal fat surrounding the viscera, have a strong association in the metabolic derangement than subcutaneous fat. Hence the body fat distribution plays a significant role in the pathogenesis of the metabolic disorders associated in obesity(14). Though many authors have found positive association between visfatin and BMI and body fat index, there is lack of studies stating the association of visfatin and atherogenic index. So in this study we tried to explore how far is the correlation of visfatin with the atherogenic index in young obese population that would relatively predict the cardiometabolic risks at an earlier stage.

METHODS

This prospective study involves 60 young obese subjects (BMI ≥ 25 kg/m² - Asian cut off) and 30 non-obese controls(BMI≤ 24.9 kg/m²).Exclusion of those subjects with co-morbidities - like Hypertension, Diabetes, Hypothyroidism, and Pregnant women, on Oral Contraceptive Pills were done. The study was conducted in compliance with Helsinki declaration 1964 and its amendments, after approval from institutional ethical committee.

All subjects were subjected to detailed history taking and clinical examination after informed written consent. Weight, Height, HC (Hip circumference) and WC (waist circumference) were measured and BMI (Body mass index) ,WHR(waist–hip ratio) was calculated. Body weight and height was measured and BMI was calculated. Waist circumference (WC), hip circumference (HC), was measured and waist-hip ratio (WHR) calculated.

After overnight fasting, six ml of blood was collected by phlebotomy in the morning, serum separated immediately and serum aliquots frozen (-80°C) on the same day, and stored until further analysis. TC (Total cholesterol), HDL-C (High-Density Lipoprotein-Cholesterol), LDL-C (Low-Density Lipoprotein-Cholesterol), and Triglycerides were determined by enzymatic procedure using the commercially available test kit (Diasys, Connecticut, United States). Very Low-Density Lipoprotein –C, was calculated using the formula, (TGL / 5). The atherogenic index of Plasma was calculated using the formula log TG/ HDL-C.

Serum concentrations of visfatin were assayed using a commercial ELISA kit (Bioain Scientific Inc, Ontario, Canada) with a lower limit of sensitivity of 0.11 ng/ml and intra assay and interassay coefficients of variations of <15% and <10%, respectively. The kit showed no cross-reactivity with any other cytokines tested.

Statistical analysis

The normal distribution of continuous variables was done using Kolmogrov-Smirnov and Shapiro –Wilk test. Student ‘t’ test was done to test the significant difference in means of the study and the control group. Significant difference for all the statistical tests, were determined by P value of <0.05. Pearson correlation was done for studying the correlation between variables.

RESULTS

After selection of age and sex matched controls, the mean age of the cases (young obese adults) was 31.75± 3.9 and that of controls (nonobese) were 31.26±3.4. (Table 1).

| Parameters            | Obese  | Control | P   |
|-----------------------|--------|---------|-----|
| Age                   | 31.75± 3.9 | 31.26±3.4 | NS  |
| Weight                | 80.0± 13.0  | 59.07± 7.1  | 0.01 |
| Height                | 160.40± 7.3 | 163.60± 6.2 | 0.011|
| BMI                   | 31.08± 3.6  | 22.22± 1.7  | 0.001|
| Waist circumference(cm)| 99.38± 5.2  | 74.40± 2.5  | 0.001|
| Hip circumference(cm) | 106.97± 3.0 | 87.53± 2.9  | 0.01 |
| Waist - Hip ratio     | 0.927± 0.098 | 0.845± 0.039 | 0.001|

Table 1: Baseline characteristics

Mean serum NAMPT/visfatin levels were higher in the young obese (15.6±2.0 ng/dl) than the controls (6.7±0.9ng/dl) with significant p value of 0.00 (Fig.1). Means of Weight, BMI, WC, HCan d waist-hip ratio were significantly higher in the obese subjects than the controls group, whereas the mean height was higher in controls than the study population, with a significant P:< 0.05. (Table 1; Fig 2).

Fig. 1: Distribution of visfatin among the study population
Obese study subjects had higher mean serum triglycerides, LDL-C, and VLDL-C than the controls. The HDL-C was lower in the obese subjects than the controls. Total cholesterol levels were equal in both the study groups (Fig. 3).

The young obese study group have significantly higher atherogenic index than controls (P < 0.016). Serum visfatin/PBEF levels in the obese subjects was positively correlated with BMI (r: 0.926), WC (r: 0.725), WHR (r: 0.659), TG (r: 0.32), LDL-C (r: 0.911) with P value<0.05 and insignificant correlation with hip circumference (Table 2).

As with correlation studies in the study group, PBEF/visfatin had positive correlation with atherogenic index (Fig. 5), BMI and atherogenic index also had positive correlation (r: 0.567 P:0.01; Table 2).

![Fig. 2: Distribution of anthropometric indices among the study population](image1)

![Fig. 3: Lipid profile in the study population](image2)

**Table 2: Correlation of serum visfatin with various parameters in obese subjects**

| Parameters          | r value | P value |
|---------------------|---------|---------|
| BMI                 | 0.926   | 0.00    |
| Waist circumference | 0.725   | 0.00    |
| Hip circumference   | 0.106   | NS      |
| Waist –Hip Ratio    | 0.659   | 0.00    |
| Triglycerides       | 0.32    | 0.04    |
| LDL-C               | 0.911   | 0.00    |
| Atherogenic index   | 0.599   | 0.00    |

![Fig. 4: Atherogenic index in the study population](image3)
DISCUSSION

We designed this study to determine the serum PBEF/visfatin in young obese adults and to demonstrate its correlation with the atherogenic index. We determined the mean age of the study population to be 31.34 ± 5.0 with 51% males and 49% females. In this study, it was seen that the serum levels of PBEF/visfatin was higher in young obese adults than the non-obese controls that were in accordance with reports of Kaminska et al., (15) in adults and there was a positive correlation between serum visfatin levels and adiposity in adolescents, according to Tuskasen et al.,(16). Regarding the anthropometric indices, the BMI and WHR was higher in obese young adults in this study and they had positive correlation with the serum visfatin levels which were in consistent to the findings of Davutoglu et al.,(17) and Berndt et al., (18).

With lipid profile, we had positive correlation of serum Triglycerides and LDL-C with visfatin, in this study and this points to an insulin-mimetic property of visfatin that have profound effects on lipid homeostasis and triglyceride metabolism.

In our study the atherogenic index was significantly higher in young obese and had positive correlation with serum visfatin with r: 0.599 (P<0.00). BMI and the Atherogenic index also had a positive correlation in obese study group (r value: 0.568 p:0.01).

Dobiasova et al.,(19) pointed AIP to be the significant predictor of cardiovascular risk for both research and for practice. Simões et al., (20) also demonstrated the atherogenic index of plasma as the best marker of atherosclerosis in their studies.

As NAMPT/visfatin being produced from various cells like monocytes, lymphocytes, neutrophils and hepatocytes apart from visceral fat, it has a significant association with various inflammatory markers that cause endothelial dysfunction (21). Moreover, Wang et al., have stated that visfatin causes smooth muscle cell proliferation through NAMPT- dependent mechanism. (22).

Thus visfatin/Nampt enhance the production of proinflammatory cytokines, activate leucocytes and synthesize various adhesion molecules those accounts together for the atherosclerotic plaque formation (23). Zheng et al., (24) in their study have proved visfatin is closely associated with atherosclerotic plaque in carotid arteries of type 2 diabetic patients. Also authors have given scientific evidences that visfatin causes destabilization of atherosclerotic plagues. (25). Hence Zheng et al have rightly stated visfatin to be the clinical marker of cardiovascular diseases.

CONCLUSION

From this study we infer that high PBEF/Visfatin, correlating with high atherogenic index in young obese adults will subsequently cause endothelial dysfunction of bloodvessels and enhance cardiometabolic risks. So we suggest that PBEF/Visfatin/NAMPT can be targeted in pharmacological research with the scope of preventing cardiovascular complications at an earlier stage.

ACKNOWLEDGEMENT

We extend our sincere thanks to all patients participated in this study

CONFLICT OF INTEREST

The authors have no conflict of interests to declare that are relevant to the content of this article.

REFERENCES

1. Tilg, H., Moschen, A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond). 2008; 114(4):275-288.
2. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
3. Sethi, J.K., Vidal-Puig, A. Visfatin: The missing link between intra-abdominal obesity and diabetes? Trends Mol Med . 2005;11(8):344-347.
4. Pradeepa, R., Anjana, R.M., Joshi, S.R., Bhansali, A., Deepa, M., Joshi, P.P.et al., Prevalence of generalized and abdominal

DOI: https://doi.org/10.51248/v42i3.1451

Biomedicine- Vol. 42 No. 3: 2022

455
Anitha et al: Circulating NAMPT/ PBEF /Visfatin and its cardiometabolic risk in young obese adults

obesity in urban and rural India-The ICMR-INDIAB Study (Phase-I) [ICMR-INDIAB-3] Indian J. Med. Res. 2015; 142:139-150.

5. Udu, S., Kebapci, N., Kara, M., Bal, C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 Diabetes mellitus. Exp Ther Med. 2012;4(1):113-120.

6. Matsuzawa, Y. The Metabolic Syndrome and Adipocytokines.FEBS Lett. 2006 22:580(12):2917-2921.

7. Araki, S., Dobashi, K., Kubo, K., Kawagoe, R., Yamamoto, Y., Kawada, Y., et al., Plasma Visfatin Concentration as a Surrogate Marker for visceral fat accumulation in obese children. Obesity (Silver Spring). 2008; 16(2):384-388.

8. Sun, G., Bishop, J., Khalili, S., Vasdev, S., Gill, V., Pace, D., et al., Serum visfatin concentrations are positively correlated with serum triacylglycerol and down regulated by overfeeding in healthy young men. Am J ClinNutr. 2007;85(2):399-404.

9. Cinar, N., Gurlek, A. Association between novel adipocytokines, adiponectin, vaspin, visfatin, and thyroid. Endocr Connect. 2013 Oct 24;2(4): R30-R38.

10. de Luis, D.A., Aller, R., Gonzalez, M.S., Conde, R., Izaola, O., de la Fuente, B. Serum visfatin levels and metabolic syndrome criteria in obese female subjects. Diabetes Metab Res Rev. 2013; 29 (7):576-581.

11. Baltaci, D., Tunec, M.C., Cetinkaya, M., Gunduz, T. Evaluation of visfatin in patients with obesity, metabolic syndrome, insulin resistance, and impaired glucose tolerance; Case-control study. Acta Medica Anatolia 2016: 4(2):61-67.

12. Grundy, S.M., Brewer, H.B. Jr, Cleeman, J.I., Smith, S.C. Jr, Lenfant, C. Definition of metabolic syndrome report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004 Jan 27;109(3):433-438.

13. Chang, Y., Li, Y., Guo, X., Dai, D., Sun, Y. The Association of ideal cardiovascular health and atherogenic index of plasma in rural population: a cross-sectional study from Northeast China. Int J Environ Res Public Health. 2016; 13(10):1027.

14. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003; 112: 1796-1808.

15. Kamińska, A., Kopeczyńska, E., Bronisz, A., Zmudzińska, M., Bieliński, M., Borkowska, A. An Evaluation of Visfatin Levels In Obese Subjects. Endo kryiol Pol. 2010; 61(2):169-173.

16. Taşkesen, D., Kirel, B., Us, T. Serum Visfatin Levels, Adiposity and Glucose Metabolism in Obese Adolescents.J Clin Res PediatrEndocrinol. 2012; 4(2):76-81.

17. Davutoglu, M., Ozkaya, M., Guler, E., Garipardic, M., Gursoy, H., Karabiber, H. Plasma Visfatin Concentrations In childhood obesity: Relationships to insulin resistance and anthropometric indices. Swiss Med Wkly. 2009; 139 (1-2):22-27.

18. Berndt, J., Klötting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schön, M.R. Plasma Visfatin Concentrations and Fat-Specific Mrna Expression in Humans. Diabetes. 2005; 54(10):2911-2916.

19. Dobiasova, M., Frohlich, J. The Plasma Parameter Log (TG/HDL-C) As an Atherogenic Index: Correlation with Lipoprotein Particle Size and Esterification Rate in Apop-Lipoprotein-Depleted Plasma (FERHDL). Clin Biochem. 2001; 34(7):583-588.

20. Simões,N.F., Domingos, A.L.G., De Oliveira, F.L.P., Caldas, E.S., Guedes, M.R., Fajardo, V.C., et al., Resistin and visfatin concentrations are related to central obesity and inflammation in Brazilian children. Nutrire. 2018; 43:1-8

21. Małyszko, J., Małyszko, J.S., Mysliwiec, M. Visfatin and Endothelial Function in Dialyzed Patients.Nephrology (Carlton). 2010; 15(2):190-196.

22. Wang, P., Xu, T.Y., Guan, Y.F., Su, D.F., Fan, G.R., Miao, C.Y. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81(2):370-380.

23. Auguet, T., Aragones, G., Guiu-Jurado, E., Berlanga, A., Curria, M., Martinez, S., et al., Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque. BMC Cardiovasc Disord. 2016;16:149(1-7).

24. Zheng, L.Y., Xu, X., Wan, R.H., Xia, S., Lu., J., Huang, Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol Metab Syndr 2019; 11:60(1-7). eCollection 2019.

25. Li, B., Zhao, Y., Liu, H., Meng, B., Wang, J., Qi, T., et al., Visfatin destabilizes atherosclerotic plaques in apolipoprotein E-deficient mice. PLoS ONE. 2016;11(2): e0148273.

DOI: https://doi.org/10.51248/v42i3.1451

Biomedicine- Vol. 42 No. 3: 2022